Sinolink: Savolitinib reaches a value inflection point, with global commercialization set to begin in 2027.

Sinolink: Savolitinib reaches a value inflection point, with global commercialization set to begin in 2027. Sinolink released a research report stating that savolitinib will reach an important milestone inflection point where excellent data translates into commercial sales growth. In the short term, the bank remains optimistic about the catalyst from two blockbuster studies of savolitinib to be presented at ESMO; in the medium to long term, the bank is also optimistic that the drug will simultaneously reach a commercialization growth inflection point in both domestic and overseas markets. Based on the above analysis, it assigns a "Buy" rating to the rights holder of savolitinib, HUTCHMED (00013). Sinolink's main points are as follows: The MET-targeted drug track is accelerating its iteration, with savolitinib leading the positioning MET gene abnormalities include MET-ex14 skipping mutations, MET activating mutations, MET gene amplification, MET gene fusion, and MET protein overexpression, among which the patient base for MET gene amplification and MET protein overexpression is relatively large. Among MET gene abnormalities, the gold standard for detecting MET gene amplification is FISH; while MET protein overexpression relies on IHC immunohistochemistry testing. Historical studies have shown that the proportion of patients positive for MET gene amplification after EGFR-TKI progression (FISH testing, GCN5 and/or MET/CEP72) is approximately 1/3, and the willingness of such patients to undergo a second biopsy is approximately 40%-50%; while C-MET protein overexpression is one of the factors inducing cancer, with high expression accounting for approximately 1/3 of NSCLC. The corresponding MET-targeted drugs are divided into three categories: small-molecule MET TKIs (such as HUTCHMED/AZ's savolitinib), anti-MET antibodies/bispecific antibodies (such as J&J's amivantamab), and C-MET ADCs (such as AbbVie's ABBV-400). Small-molecule MET-TKIs are currently the mainstream clinical medication. 2L EGFRmt/METamp welcomes a key breakthrough, with savolitinib presenting global clinical results at ESMO in the highest format EGFR mutation is one of the largest mutation factors among NSCLC patients. In 2025 alone, global sales of osimertinib (an EGFR-TKI) had reached US$7.254 billion, of which an estimated 3/4 was from the 1L market. After EGFR-TKI resistance lies a massive market, in which MET gene abnormalities account for a large proportion. The bank estimates that the neutral forecast market size for 2L treatment of EGFRmt MET-amplified NSCLC is approximately US$700 million. Previously, the diagnosis and treatment of 2L EGFRmt/METamp NSCLC was relatively blank, but the treatment landscape is now becoming clearer: both CSCO (China's authoritative guideline) and NCCN (the US authoritative guideline) increasingly emphasize MET amplification testing, with CSCO having upgraded MET amplification testing from a Class II recommendation to Class I in 2026, accompanied by the emergence and popularization of MET-targeted drugssavolitinib, as the only drug to achieve Phase III clinical success in this indication, will be launched in China and globally and is expected to maintain a relatively long period of commercialization exclusivity. Around 2L EGFRmt/MET-amplified NSCLC, HUTCHMED/AZ have laid out three studies: SACHIa China Phase III study (results already announced, ITT mPFS=8.2mo vs. 4.5mo, HR=0.34; mOS=22.9mo vs. 17.7mo, HR=0.84); SAVANNAHa global Phase II clinical trial (results already announced, ITT mPFS=7.4mo, Asian mPFS=7.6mo); SAFFRONa global Phase III study (mPFS=7.6mo vs. 5.4mo, HR=0.55; mOS=17.8mo vs. 12.9mo, HR=0.68). Savolitinib demonstrates prominent efficacy in this patient population. 1L EGFRmt/MET-overexpressed NSCLC has large unmet clinical needs, and savolitinib will maintain exclusivity for a relatively long time Currently, none of the relevant guidelines have a clear and independent diagnostic and treatment pathway for EGFRmt/MET-overexpressed NSCLC, so this market has huge unmet needs. Savolitinib is expected to become the first drug launched in this marketits registrational Phase III clinical results were announced in LBA form on October 26, 2026 (mPFS=24.8mo vs. 11.1mo, HR=0.45; mOS=44.5mo vs. 34.9mo, HR=0.48), after which HUTCHMED plans to submit a marketing application in China by the end of 2026 for a new indication of savolitinib for first-line treatment. Breaking through the ceiling of a single indication, the second curve drives explosive growth of savolitinib both domestically and internationally Savolitinib not only has data catalysts at ESMOboth datasets were released in the high-specification LBA formatbut more importantly, savolitinib will also reach an important milestone inflection point where excellent data translates into commercial sales growth: looking back, savolitinib was previously trapped in the red-ocean market of MET-ex14 skipping NSCLC, and its sales were mediocre; however, starting in 2027, the drug is expected to see explosive growth: Domestically, for 2L EGFRmt/METamp NSCLC, AZ will drive medical insurance negotiations in 2026, and for 1L EGFRmt/MET-overexpressed NSCLC, the final results of the Phase III registrational study SANOVO will be announced on October 26, 2026, after which HUTCHMED and AZ are expected to push for NDA submission for this indication as soon as possible. Overseas, AZ submitted an NDA to the FDA on September 29, 2026 for the 2L EGFRmt/METamp NSCLC indication. The new indications all use the combination with osimertinib regimen, which will improve the sales ecosystem of AZ's blockbuster osimertinib and extend the life cycle of osimertinib, thereby greatly mobilizing AZ's enthusiasm to promote the commercial sales of savolitinib. Risk warnings Risk of MET gene abnormality detection rate falling short of expectations, risk of deterioration in the competitive landscape, clinical data falling short of expectations, medical insurance negotiations falling short of expectations, and launch progress falling short of expectations.